Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects

Sitbon, O; Beghetti, Maurice; Petit, J; Iserin, L; Humbert, M; Gressin, V; Simonneau, G

doi:10.1111/j.1365-2362.2006.01685.x

Scientific article

English

Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects

ContributorsSitbon, O; Beghetti, Maurice; Petit, J; Iserin, L; Humbert, M; Gressin, V; Simonneau, G

Published inEuropean journal of clinical investigation, vol. 36 Suppl 3, p. 25-31

Publication date2006

Abstract

Bosentan is an effective first-line therapy in New York Heart Association (NYHA) III patients with idiopathic pulmonary arterial hypertension (PAH). Pre-clinical data support the rationale for the potential benefit of bosentan in PAH associated with congenital heart disease (CHD).

Keywords

Adolescent
Adult
Antihypertensive Agents/administration & dosage
Child
Drug Therapy, Combination
Exercise Test/methods
Female
Heart Defects, Congenital/complications/physiopathology
Humans
Hypertension, Pulmonary/complications/drug therapy/physiopathology
Male
Middle Aged
Prostaglandins, Synthetic/therapeutic use
Pulmonary Circulation/drug effects
Retrospective Studies
Sulfonamides/administration & dosage
Treatment Outcome
Vascular Resistance/drug effects
Walking/physiology

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de pédiatrie, gynécologie et obstétrique

Research groups

L'hypertension pulmonaire (pédiatrie) (228)

Citation (ISO format)

SITBON, O et al. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects. In: European journal of clinical investigation, 2006, vol. 36 Suppl 3, p. 25–31. doi: 10.1111/j.1365-2362.2006.01685.x

Article (Published version)

Identifiers

PID : unige:46926
DOI : 10.1111/j.1365-2362.2006.01685.x
PMID : 16919007

Journal ISSN0014-2972

497views

0downloads

Creation03/02/2015 14:19:00

First validation03/02/2015 14:19:00

Update14/03/2023 22:52:02

Status update14/03/2023 22:52:02

Last indexation30/10/2024 22:58:17

Archive ouverte UNIGE

Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects

Bosentan is an effective first-line therapy in New York Heart Association (NYHA) III patients with idiopathic pulmonary arterial hypertension (PAH). Pre-clinical data support the rationale for the potential benefit of bosentan in PAH associated with congenital heart disease (CHD).

Technical informations